-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Medical Network, August 6 News On August 4, Jianyou shares announced that the company's subsidiary Hong Kong Jianyou recently received an ANDA approval notice for carmustine for injection issued by the FDA (application number 213460)
.
According to data from Mi Nei.
com, since 2021, Jianyou shares have been approved for 10 ANDAs (based on application numbers) in the United States
.
.
According to data from Mi Nei.
com, since 2021, Jianyou shares have been approved for 10 ANDAs (based on application numbers) in the United States
.
Carmustine for injection is a nitrosourea compound developed by Emcure, which can be used as a single drug or in combination with other drugs to treat brain tumor glioblastoma, brain stem glioma, multiple myeloma, Hodgkin's lymphoma and so on
.
.
At present, many companies in the US market have approved carmustine generic drugs for injection, while in the domestic market, carmustine injections from two companies, Tianjin Jinyao Pharmaceutical and Hebei Beitu Pharmaceutical, are on sale
.
.
According to data from Meinnet.
com, including carmustine, Jianyou shares have been approved for 10 ANDAs in the United States since 2021, involving 9 products, all of which are injections
.
com, including carmustine, Jianyou shares have been approved for 10 ANDAs in the United States since 2021, involving 9 products, all of which are injections
.
ANDA approved by Jianyou shares since 2021
Source: Meinenet Global Listed Drug Library
Among the 9 products, Jianyou Co.
, Ltd.
submitted an application for the listing of tigecycline for injection in the imitation of 4 categories in July 2020, and it is still in the status of "under review and approval"
.
At present, 8 domestic companies have approved the production of this product, among which the products of Hisun and Hausen have been reviewed
.
, Ltd.
submitted an application for the listing of tigecycline for injection in the imitation of 4 categories in July 2020, and it is still in the status of "under review and approval"
.
At present, 8 domestic companies have approved the production of this product, among which the products of Hisun and Hausen have been reviewed
.
Source: Mi Nei.
com database, announcement of listed companies
com database, announcement of listed companies
Medical Network, August 6 News On August 4, Jianyou shares announced that the company's subsidiary Hong Kong Jianyou recently received an ANDA approval notice for carmustine for injection issued by the FDA (application number 213460)
.
According to data from Mi Nei.
com, since 2021, Jianyou shares have been approved for 10 ANDAs (based on application numbers) in the United States
.
.
According to data from Mi Nei.
com, since 2021, Jianyou shares have been approved for 10 ANDAs (based on application numbers) in the United States
.
Carmustine for injection is a nitrosourea compound developed by Emcure, which can be used as a single drug or in combination with other drugs to treat brain tumor glioblastoma, brain stem glioma, multiple myeloma, Hodgkin's lymphoma and so on
.
.
At present, many companies in the US market have approved carmustine generic drugs for injection, while in the domestic market, carmustine injections from two companies, Tianjin Jinyao Pharmaceutical and Hebei Beitu Pharmaceutical, are on sale
.
.
According to data from Meinnet.
com, including carmustine, Jianyou shares have been approved for 10 ANDAs in the United States since 2021, involving 9 products, all of which are injections
.
com, including carmustine, Jianyou shares have been approved for 10 ANDAs in the United States since 2021, involving 9 products, all of which are injections
.
ANDA approved by Jianyou shares since 2021
Source: Meinenet Global Listed Drug Library
Among the 9 products, Jianyou Co.
, Ltd.
submitted an application for the listing of tigecycline for injection in the imitation of 4 categories in July 2020, and it is still in the status of "under review and approval"
.
At present, 8 domestic companies have approved the production of this product, among which the products of Hisun and Hausen have been reviewed
.
, Ltd.
submitted an application for the listing of tigecycline for injection in the imitation of 4 categories in July 2020, and it is still in the status of "under review and approval"
.
At present, 8 domestic companies have approved the production of this product, among which the products of Hisun and Hausen have been reviewed
.
Source: Mi Nei.
com database, announcement of listed companies
com database, announcement of listed companies
Medical Network, August 6 News On August 4, Jianyou shares announced that the company's subsidiary Hong Kong Jianyou recently received an ANDA approval notice for carmustine for injection issued by the FDA (application number 213460)
.
According to data from Mi Nei.
com, since 2021, Jianyou shares have been approved for 10 ANDAs (based on application numbers) in the United States
.
.
According to data from Mi Nei.
com, since 2021, Jianyou shares have been approved for 10 ANDAs (based on application numbers) in the United States
.
Carmustine for injection is a nitrosourea compound developed by Emcure, which can be used as a single drug or in combination with other drugs to treat brain tumor glioblastoma, brain stem glioma, multiple myeloma, Hodgkin's lymphoma and so on
.
Tumor tumor tumor.
At present, many companies in the US market have approved carmustine generic drugs for injection, while in the domestic market, carmustine injections from two companies, Tianjin Jinyao Pharmaceutical and Hebei Beitu Pharmaceutical, are on sale
.
.
According to data from Meinnet.
com, including carmustine, Jianyou shares have been approved for 10 ANDAs in the United States since 2021, involving 9 products, all of which are injections
.
com, including carmustine, Jianyou shares have been approved for 10 ANDAs in the United States since 2021, involving 9 products, all of which are injections
.
ANDA approved by Jianyou shares since 2021
Source: Meinenet Global Listed Drug Library
Among the 9 products, Jianyou Co.
, Ltd.
submitted an application for the listing of tigecycline for injection in the imitation of 4 categories in July 2020, and it is still in the status of "under review and approval"
.
At present, 8 domestic companies have approved the production of this product, among which the products of Hisun and Hausen have been reviewed
.
Enterprise business enterprise, Ltd.
submitted an application for the listing of tigecycline for injection in the imitation of 4 categories in July 2020, and it is still in the status of "under review and approval"
.
At present, 8 domestic companies have approved the production of this product, among which the products of Hisun and Hausen have been reviewed
.
Source: Mi Nei.
com database, announcement of listed companies
com database, announcement of listed companies
